Ije Nwokori Acquires 179 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori purchased 179 shares of Dr. Martens stock in a transaction on Tuesday, August 11th. The stock was bought at an average cost of GBX 84 per share, with a total value of £150.36.

Ije Nwokori also recently made the following trade(s):

• On Thursday, June 25th, Ije Nwokori acquired 118,516 shares of Dr. Martens stock. The stock was bought at an average price of GBX 72 per share, for a total transaction of £85,331.52.
• On Thursday, June 11th, Ije Nwokori purchased 202 shares of Dr. Martens stock. The stock was bought at an average price of GBX 74 per share, for a total transaction of £149.48.
• On Friday, June 12th, Ije Nwokori bought 112,500 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 76 per share, with a total value of £85,500.

Dr. Martens Trading Up 0.7%

LON DOCS traded up GBX 0.60 during mid-day trading on Thursday, reaching GBX 88.80. 18,918,002 shares of the stock were exchanged, compared to its average volume of 7,381,275. The stock has a 50 day simple moving average of GBX 74.52 and a 200-day simple moving average of GBX 69.18. Dr. Martens plc has a one year low of GBX 59.15 and a one year high of GBX 100.87. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. The stock has a market cap of £849.92 million, a P/E ratio of 37.00, a P/E/G ratio of 6.40 and a beta of 0.26.

Dr. Martens (LON:DOCS) last released its earnings results on Tuesday, May 19th. The company reported GBX 4.20 EPS for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.The business had revenue of £764.90 million during the quarter. On average, analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 100 price objective on shares of Dr. Martens in a research report on Tuesday, June 2nd. Berenberg Bank lowered their price objective on shares of Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Dr. Martens currently has an average rating of “Moderate Buy” and a consensus target price of GBX 105.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.